Friedrich Bayer and Johann Friedrich Weskott establish a dyestuffs factory in Barmen. 18 years later, it is changed into the joint-stock company Farbenfabriken vorm. Friedr. Bayer & Co.
Chemist Carl Duisberg begins his career at Bayer. Under his management, Bayer scientists should come to make pioneering discoveries.
The pharmaceutical department is established.
Aspirin® is registrered as a trade mark and becomes the world’s favorite pain killer.
The company’s headquarters is transferred to Leverkusen.
Bayer researcher Gerhard Domagk is awarded the Nobel Prize for Medicine for his discovery of the antibacterial effect of the sulfonamides (Prontosil).
The company changes its name to Bayer AG.
Bayer becomes the first German industrial company to be listed on the Tokyo Stock Exchange.
Bayer marks the 100th birthday of Aspirin® by having professional mountaineers wrap Bayer’s former high-rise headquarters building in Leverkusen, transforming it into the world’s biggest Aspirin® pack and earning the company three entries in the Guinness Book of Records.
The acquisition of the polyols business Lyondell Chemical Company makes Bayer the world’s biggest producer of raw materials for polyurethanes.
Bayer acquires Aventis CropScience making it a world leader in crop protection.
In December, Bayer’s management announces plans to establish independent operating subsidiaries under the umbrella of a management holding company. This is the beginning of Bayer CropScience, Bayer HealthCare, Bayer Chemicals and Bayer MaterialScience.
The Bayer shares are listed for the first time on the New York Stock Exchange.
WHO includes acetylsalicylic acid, the active ingredient in Aspirin®, in its “List of essential medicines”.
Levitra®, the erectile dysfunction drug, is registrered in Europe. Today Levitra® is registrered in more than 80 countries around the world.
Bayer becomes the first private-sector partner to UNEP (United Nations Environment Programme) in the area of youth and environment.
Bayer is one of the world’s top three suppliers of non-prescription medicines after the acquisition of the Roche OTC business.
Lanxess AG is spun off from the Bayer Group. Lanxess continues Bayer’s chemical business in Bayer Chemicals and parts of the polymer business.
In December, the U.S. Food and Drug Administration approves Sorafenib (Nexavar®), an active ingredient jointly developed by Bayer HealthCare and Onyx Pharmaceuticals Inc., for the treatment of advanced renal cell carcinoma.
Bayer launches the Group-wide innovation initiative “Triple-i: inspiration, ideas and innovation”, which calls on all employees worldwide to participate in the search for new product, development and business ideas.
Bayer completes the acquisition of Schering AG and becomes one of the leading players on the market for specialized pharmaceuticals.
Read Bayer’s entire history